Chr. Hansen acquires HSO Health Care to grow probiotics offering for women’s health

Date 04.21.2020 | Category: News
| Comments:

Chr Hansen HSO IDM Apr20

Chr. Hansen Holding A/S and HSO Health Care GmbH today entered into an agreement, under which Chr. Hansen will acquire HSO Health Care. The acquisition of the Austria-based B2B company specialising in probiotics for women’s health will strengthen and expand Chr. Hansen’s global microbial platform. This acquisition is aligned with the strategy of pursuing bolt-on acquisitions that fit into the microbial platform, as outlined in the Nature’s no. 1 strategy. The transaction will be finalised later this week.


Said Mauricio Graber, CEO of Chr. Hansen “I am excited that we have reached an agreement with HSO Health Care, which has demonstrated very fast growth through a globally recognised portfolio that complements our own UREX products nicely. Women’s health is a high-growth segment where innovation is becoming increasingly important, and with the addition of the Astarte™ portfolio we will be able to deliver innovation to a much larger market more quickly.”


Added Helmut Essl, CEO of HSO Health Care GmbH: “HSO Health Care has been working from a mindset of scientifically documented, natural products since our inception, and we are delighted that with the addition of the Astarte products to Chr. Hansen, we can make an even greater impact on a global scale. I am very excited that Chr. Hansen will now bring Astarte™ to the next level.”


A scientific approach to common urogenital discomforts

Urogenital discomfort is a concern for women all over the world who are increasingly looking for intimate care products based on natural ingredients. This has driven the category for women’s health to be among the fastest-growing in the probiotics market. Mauricio Graber concludes; “Chr. Hansen is committed to keep unleashing the Power of Good Bacteria™, and I am proud that we will now strengthen our offering of probiotic concepts for women that can help to enable a balanced female microbiota, ultimately contributing to their well-being and quality of life.”



• Women’s health is one of the fastest growing probiotic segments, with an estimated market CAGR of more than 15% since 2015, which HSO has outperformed substantially

• Good fit to Chr. Hansen with easy integration and strong potential synergies

• Strengthens and expands Chr. Hansen’s microbial platform by adding HSO’s branded portfolio Astarte, a global award-winning line of patented probiotic products for women’s health

• Clinically documented and using four specific strains, Astarte has a powerful selling proposition and a strong brand position and is sold in multiple channels

• Strengthens our women’s health offering by combining Astarte with Chr. Hansen’s UREX products, creating a portfolio that can be leveraged globally and expanded into new adjacencies within women’s health

• Expected 2020 revenues of approximately EUR 15 million, with an EBITDA margin above 40%. Strong double-digit organic growth expected from 2020-2025

• Chr. Hansen’s outlook for 2019/20 is unchanged

For more visit


Source: Chr Hansen
Author: COX
Load more news » Loading news